Welcome to our dedicated page for IGM Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IGM Biosciences filings document corporate-status and capital-structure matters for the company's common stock. Recent records include Form 25 removal of the common stock from Nasdaq listing and registration and Form 15 termination of registration or suspension of Exchange Act reporting duties for the same class of securities.
The filing record also includes an 8-K reporting a material definitive agreement, securities registered under Section 12(b), and public-company disclosures tied to governance, stockholder communications, and changes in the company's office-lease arrangements. These documents frame IGMS through its common stock, reporting obligations, and formal corporate-status disclosures.
IGM Biosciences (IGMS) Form 4 filing – CFO Misbah Tahir reported a small automatic sale linked to restricted stock units (RSUs).
- Transaction details: On 06/16/2025, 1,522 common shares were sold at a weighted-average price of $1.1992 in multiple trades ranging from $1.17-$1.22.
- Purpose: Shares were sold solely to satisfy tax-withholding obligations arising from the vesting of RSUs (per footnote 1).
- Ownership post-sale: Tahir now directly owns 178,802 shares of IGMS common stock.
The filing does not disclose any open-market discretionary selling and therefore appears routine. The CFO retains more than 99% of his pre-sale position, suggesting ongoing alignment with shareholders. No derivative transactions or additional insider activity were reported.
IGM Biosciences Chief Executive Officer and Director Mary Beth Harler reported a Form 4 filing on June 28, 2025, disclosing a transaction that occurred on June 16, 2025.
Key transaction details:
- Sold 1,522 shares of Common Stock at a weighted average price of $1.1992 per share
- The sale was specifically to cover tax withholding obligations related to the vesting of restricted stock units
- Following the transaction, Harler maintains direct beneficial ownership of 338,181 shares
The transaction was executed through multiple trades with prices ranging from $1.17 to $1.22 per share. The filing was signed by Misbah Tahir via power of attorney on June 20, 2025.